Chemical Formula: C11H16N4O4

Chemical Formula C11H16N4O4

Found 27 metabolite its formula value is C11H16N4O4

Pentostatin

(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol

C11H16N4O4 (268.1171496)


Pentostatin is only found in individuals that have used or taken this drug. It is a potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. [PubChem]Pentostatin is a potent transition state inhibitor of adenosine deaminase (ADA), the greatest activity of which is found in cells of the lymphoid system. T-cells have higher ADA activity than B-cells, and T-cell malignancies have higher activity than B-cell malignancies. The cytotoxicity that results from prevention of catabolism of adenosine or deoxyadenosine is thought to be due to elevated intracellular levels of dATP, which can block DNA synthesis through inhibition of ribonucleotide reductase. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Cytotoxicity is cell cycle phase-specific (S-phase). D000970 - Antineoplastic Agents > D000903 - Antibiotics, Antineoplastic > D005573 - Formycins L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents D004791 - Enzyme Inhibitors > D058892 - Adenosine Deaminase Inhibitors C471 - Enzyme Inhibitor > C2157 - Adenosine Deaminase Inhibitor

   

Razoxane

Razoxane

C11H16N4O4 (268.1171496)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D054659 - Diketopiperazines D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents D050258 - Mitosis Modulators

   

N-acetylcarnosine

(2R)-2-({1-hydroxy-3-[(1-hydroxyethylidene)amino]propylidene}amino)-3-(1H-imidazol-5-yl)propanoate

C11H16N4O4 (268.1171496)


N-Acetylcarnosine (NAC) is a naturally-occurring compound chemically related to the dipeptide carnosine. Its molecular structure is similar to carnosine with the exception that it carries an additional acetyl group. This makes NAC a more stable molecule which is not easily destroyed by carnosinase, an enzyme that breaks down carnosine to its constituent amino acids, beta-alanine and histidine.; NAC is a free-radical scavenger and is particularly active against lipid peroxidation in the different parts of the lens in the eye. It is the active ingredient of eye drops used in order to prevent or treat cataract. [HMDB] N-Acetylcarnosine (NAC) is a naturally-occurring compound chemically related to the dipeptide carnosine. Its molecular structure is similar to carnosine with the exception that it carries an additional acetyl group. This makes NAC a more stable molecule which is not easily destroyed by carnosinase, an enzyme that breaks down carnosine to its constituent amino acids, beta-alanine and histidine. NAC is a free-radical scavenger and is particularly active against lipid peroxidation in the different parts of the lens in the eye. It is the active ingredient of eye drops used in order to prevent or treat cataract. N-Acetylcarnosine, a natural histidine-containing dipeptide, is a source of pharmacological principal L-carnosine. N-Acetylcarnosine is a potent ophthalmic agent in human cataracts[1].

   

Dexrazoxane

4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione

C11H16N4O4 (268.1171496)


An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]. The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D054659 - Diketopiperazines D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents D050258 - Mitosis Modulators D004791 - Enzyme Inhibitors

   

Hydroxyprolyl-Histidine

2-{[hydroxy(4-hydroxypyrrolidin-2-yl)methylidene]amino}-3-(1H-imidazol-5-yl)propanoate

C11H16N4O4 (268.1171496)


Hydroxyprolyl-Histidine is a dipeptide composed of hydroxyproline and histidine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Histidylhydroxyproline

(2S,4R)-1-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]-4-hydroxypyrrolidine-2-carboxylic acid

C11H16N4O4 (268.1171496)


Histidinylhydroxyproline is a dipeptide composed of histidine and hydroxyproline. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

(8R)-3-[(4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol

(8R)-3-[(4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol

C11H16N4O4 (268.1171496)


D000970 - Antineoplastic Agents > D000903 - Antibiotics, Antineoplastic > D005573 - Formycins D004791 - Enzyme Inhibitors > D058892 - Adenosine Deaminase Inhibitors

   

Razoxane, (R)-

4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione

C11H16N4O4 (268.1171496)


   

N-Acetylcarnosine

2-({1-hydroxy-3-[(1-hydroxyethylidene)amino]propylidene}amino)-3-(1H-imidazol-5-yl)propanoate

C11H16N4O4 (268.1171496)


   

N-Acetylcarnosine

N-Acetylcarnosine

C11H16N4O4 (268.1171496)


A dipeptide that is the N-acetyl derivative of carnosine. MS2 deconvoluted using MS2Dec from all ion fragmentation data, MetaboLights identifier MTBLS1040; BKAYIFDRRZZKNF-VIFPVBQESA-N_STSL_0185_N-acetyl-L-carnosine_0500fmol_180425_S2_LC02_MS02_25; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. MS2 deconvoluted using CorrDec from all ion fragmentation data, MetaboLights identifier MTBLS1040; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I.

   

PENTOSTATIN

PENTOSTATIN

C11H16N4O4 (268.1171496)


A member of the class of coformycins that is coformycin in which the hydroxy group at position 2 is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. D000970 - Antineoplastic Agents > D000903 - Antibiotics, Antineoplastic > D005573 - Formycins L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents D004791 - Enzyme Inhibitors > D058892 - Adenosine Deaminase Inhibitors C471 - Enzyme Inhibitor > C2157 - Adenosine Deaminase Inhibitor

   

N-Acetyl-carnosine; LC-tDDA; CE10

N-Acetyl-carnosine; LC-tDDA; CE10

C11H16N4O4 (268.1171496)


   

N-Acetyl-carnosine; LC-tDDA; CE20

N-Acetyl-carnosine; LC-tDDA; CE20

C11H16N4O4 (268.1171496)


   

N-Acetyl-carnosine; LC-tDDA; CE30

N-Acetyl-carnosine; LC-tDDA; CE30

C11H16N4O4 (268.1171496)


   

N-Acetyl-carnosine; LC-tDDA; CE40

N-Acetyl-carnosine; LC-tDDA; CE40

C11H16N4O4 (268.1171496)


   
   

Dexrazoxane

Dexrazoxane

C11H16N4O4 (268.1171496)


V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AF - Detoxifying agents for antineoplastic treatment D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D054659 - Diketopiperazines D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents D004791 - Enzyme Inhibitors

   

Hpro-his

1-[2-amino-3-(1H-imidazol-5-yl)propanoyl]-4-hydroxypyrrolidine-2-carboxylic acid

C11H16N4O4 (268.1171496)


   

His-HPro

2-[(4-hydroxypyrrolidin-2-yl)formamido]-3-(1H-imidazol-5-yl)propanoic acid

C11H16N4O4 (268.1171496)


   

7-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine-2-carboxylic acid

7-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine-2-carboxylic acid

C11H16N4O4 (268.1171496)


   

7-(TERT-BUTOXYCARBONYL)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE-3-CARBOXYLIC ACID

7-(TERT-BUTOXYCARBONYL)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE-3-CARBOXYLIC ACID

C11H16N4O4 (268.1171496)


   

4,4-Propane-1,3-diyldipiperazine-2,6-dione

4,4-Propane-1,3-diyldipiperazine-2,6-dione

C11H16N4O4 (268.1171496)


   

Acetylcarnosine

N-Acetyl-L-carnosine

C11H16N4O4 (268.1171496)


N-Acetylcarnosine, a natural histidine-containing dipeptide, is a source of pharmacological principal L-carnosine. N-Acetylcarnosine is a potent ophthalmic agent in human cataracts[1].

   

Histidinyl-hydroxyproline

Histidinyl-hydroxyproline

C11H16N4O4 (268.1171496)


   

(2,6-Dimethylmorpholin-4-yl)-(1-methyl-5-nitropyrazol-4-yl)methanone

(2,6-Dimethylmorpholin-4-yl)-(1-methyl-5-nitropyrazol-4-yl)methanone

C11H16N4O4 (268.1171496)


   

6-[(4-hydroxybutyl)amino]-5-[(E)-(2-oxopropylidene)amino]pyrimidine-2,4(1H,3H)-dione

6-[(4-hydroxybutyl)amino]-5-[(E)-(2-oxopropylidene)amino]pyrimidine-2,4(1H,3H)-dione

C11H16N4O4 (268.1171496)


   

Hydroxyprolyl-Histidine

Hydroxyprolyl-Histidine

C11H16N4O4 (268.1171496)